Comparative Pharmacology
Head-to-head clinical analysis: ARNUITY ELLIPTA versus BUDESONIDE INHALED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARNUITY ELLIPTA versus BUDESONIDE INHALED.
ARNUITY ELLIPTA vs Budesonide (Inhaled)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluticasone furoate is a synthetic trifluorinated corticosteroid with potent anti-inflammatory activity. It binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators such as cytokines, prostaglandins, and leukotrienes. This reduces airway inflammation and hyperresponsiveness.
Budesonide is a glucocorticoid receptor agonist that binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators such as cytokines and chemokines, and suppression of airway inflammation.
1 inhalation (100 mcg fluticasone furoate) once daily via oral inhalation, with or without a spacer.
200-800 mcg twice daily via inhalation. Maximum 1600 mcg/day.
None Documented
None Documented
The terminal elimination half-life of fluticasone furoate is approximately 24 hours. This long half-life supports once-daily dosing and contributes to sustained anti-inflammatory effects in the lungs.
Terminal elimination half-life is 2-3 hours in adults, reflecting rapid clearance. Clinical context: duration of anti-inflammatory effect may exceed half-life due to receptor binding.
Fluticasone furoate is eliminated primarily via hepatic metabolism and subsequent biliary excretion. Following oral administration, approximately 90% of the dose is excreted in feces as metabolites, with less than 1% excreted unchanged in urine. Renal excretion of unchanged drug is negligible.
Primarily hepatic metabolism via CYP3A4; metabolites are excreted in urine (~60%) and feces (~40%). Less than 10% of unchanged drug is recovered in urine.
Category C
Category A/B
Inhaled Corticosteroid
Inhaled Corticosteroid